BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News Nov 21, 2013
Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.
David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017